Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles

Veterinary Therapeutics

Volumn 3, Issue 3, 2002, Pages

  Mauldin, Glenna ^a   Truax, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS);

EID: 79251526897     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Madewell BR, Leighton RL, Theilen GH: Amputation and doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer 14:287-293, 1978.
2. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK: Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 2:177-180, 1988.
3. Mauldin GN, Matus RE, Patnaik AK, Bond BR, Mooney SC: Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 2:60-65, 1988.
4. Moore AS, Cotter SM, Frimberger AE, Wood CA, Rand WM, L'Heureaux DA: A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. J Vet Intern Med 10:372-375, 1996.
5. Barber LG, Sorenmo KU, Cronin KL, Shofer FS: Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc 36:416-421, 2000.
6. Myers NC, Moore AS, Rand WM, et al: Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 11:333-339, 1997.
7. Ogilvie GK, Reynolds HA, Richardson RC, et al: Phase II evaluation of doxorubicin for treatment of various canine neoplasms. JAVMA 195:1580-1583, 1989.
8. Sorenmo KU, Jeglum KA, Helfand SC: Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 7:370-376, 1993.
9. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53:461-470, 1996.
10. Gasparini M: Anthracycline cardiotoxicity. Pediatr Hematol Oncol 11:237-240, 1994.
11. Jain D: Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 7:53-62, 2000.
12. Loar AS, Susaneck SJ: Doxorubicin-induced cardiotoxicity in five dogs. Semin Vet Med Surg (Small Anim) 1:68-71, 1986.
13. Mauldin GE, Fox PR, Patnaik AK, Bond BR, Mooney SC, Matus RE: Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med 6:82-88, 1992.
14. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP: Doxorubicin cardiotoxicity. Cancer Treat Rev 9:149-164, 1982.
15. Fischer JG, Tackett RL, Howerth EW, Johnson MA: Copper and selenium deficiencies do not enhance the cardiotoxicity in rats due to chronic doxorubicin treatment. J Nutr 122:2128-2137, 1992.
16. Hershko C, Link G, Tzahor M, Pinson A: The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 11:207-214, 1993.
17. Mott MG: Anthracycline cardiotoxicity and its prevention. Ann NY Acad Sci 824:221-228, 1997.
18. Olson RD, Boerth RC, Gerber JG, Nies AS: Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29:1393-1401, 1981.
19. Paglia DE, Radcliffe RW: Anthracycline cardiotoxicity in a black rhinoceros (Diceros bicornis): Evidence for impaired antioxidant capacity compounded by iron overload. Vet Pathol 37:86-88, 2000.
20. Porembka DT, Lowder JN, Orlowski JP, Bastulli J, Lockrem J: Etiology and management of doxorubicin cardiotoxicity. Crit Care Med 17:569-572, 1989.
21. Van Vleet JF, Greenwood L, Ferrans VJ, Rebar AH: Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res 39:997-1010, 1978.
22. Ogilvie GK, Obradovich JE, Elmslie RE, et al: Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors. JAVMA 198:1613-1617, 1991.
23. Lucroy MD, Phillips BS, Kraegel SA, Simonson ER, Madewell BR: Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 12:325-329, 1998.
24. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31:205-213, 1992.
25. Pincus R, Goldman ID: Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance. Biochem Pharmacol 40:2625-2635, 1990.
26. Ogilvie GK, Obradovich JE, Elmslie RE, et al: Efficacy of mitoxantrone against various neoplasms in dogs. JAVMA 198:1618-1621, 1991.
27. Moore AS, Ogilvie GK, Ruslander D, et al: Evaluation of mitoxantrone for the treatment of lymphoma in dogs. JAVMA 204:1903-1905, 1994.
28. Kochevar DT, Middendorf DL, Mealey KL, et al: Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in cats. J Vet Pharmacol Ther 18:471-475, 1995.
29. Yung WK: In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12:197-203, 1989.
30. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89:271-277, 1986.
31. Ruben RL, Neubauer RH: Semiautomated colorimetric assay for in vitro screening of anticancer compounds. Cancer Treat Rep 71:1141-1149, 1987.
32. Labro MT, Abdelghaffar H: Immunomodulation by macrolide antibiotics. J Chemother 13:3-8, 2001.
33. Huff AC, Kreuzer KN: Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem 265:20496-20505, 1990.
34. Henriksson R, Holm S, Littbrand B: Interactions between antibiotics and antineoplastic drugs on antibacterial activity in vitro. Acta Oncol 29:43-46, 1990.
35. Batra VK, Morrison JA, Woodward DL, Siverd AS, Yacobi A: Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev 17:311-329, 1986.